Yo Ma lite Ma In rel par to rel	erature review anuscript number (if known) the interest of transparency ated to the content of your rties whose interests may be transparency and does not r ationship/activity/interest,	: , we ask you to disclose all manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	of advanced cervical adenocarcinoma: case report and relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the profit of th	
The to me	e author's relationships/acti the epidemiology of hyperte edication, even if that medic	ension, you should declare ation is not mentioned in topport for the work reported	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other iten	!
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone		
		Time from	26 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastXNone	36 months	
}	Royalties or licenses	XNone		

Consulting fees

4

		<u> </u>			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone			
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			
Ple	Please summarize the above conflict of interest in the following box:				

None.			

_				
	te:Dec. 14, 2021			
	ur Name: Yuqi Jiang			
		lizumab for the treatment	of advanced cervical adenocarcinoma: case report and	
	erature review			
M	anuscript number (if known)	:		
In	the interest of transparency	, we ask you to disclose al	I relationships/activities/interests listed below that are	
rel	ated to the content of your	manuscript. "Related" me	ans any relation with for-profit or not-for-profit third	
pa	rties whose interests may be	e affected by the content	of the manuscript. Disclosure represents a commitment	
-		-	. If you are in doubt about whether to list a	
	ationship/activity/interest,		•	
	,	io io procedura di activo a		
Th	o following questions annly	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
	•	to the author's relationshi	ips/activities/interests as they relate to the current	
1116	anuscript only.			
-1			defined by a discount of the control	
	•		defined broadly. For example, if your manuscript pertains	
		•	e all relationships with manufacturers of antihypertensive	
me	edication, even if that medic	ation is not mentioned in	the manuscript.	
In	item #1 below, report all su <sub>l</sub>	pport for the work reporte	ed in this manuscript without time limit. For all other item	۱S,
th	e time frame for disclosure is	s the past 36 months.		
		•		
		T		
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	al planning of the work	
	All support for the present	X None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	t 36 months	
<u>-</u>	Grants or contracts from	XNone		
	any entity (if not indicated			
	in item #1 above).			
}	Royalties or licenses	XNone		

Consulting fees

4

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone				
6	Payment for expert testimony	XNone				
7	Support for attending meetings and/or travel	XNone				
8	Patents planned, issued or pending	XNone				
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone				
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone				
11	Stock or stock options	XNone				
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None				
13	Other financial or non- financial interests	XNone				
Ple	Please summarize the above conflict of interest in the following box:					

None.			

Yo Ma lite Ma In rel pa to rel	erature review anuscript number (if known) the interest of transparency ated to the content of your rties whose interests may be transparency and does not a ationship/activity/interest,	lizumab for the treatment  i, we ask you to disclose a manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d	
	nuscript only.	to the author's relations	nips/activities/interests as they relate to the current
to me	the epidemiology of hypertoedication, even if that medic	ension, you should declar ation is not mentioned in pport for the work report	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

4

		<u> </u>			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone			
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			
Ple	Please summarize the above conflict of interest in the following box:				

None.			

Yo Ma lite Ma In rel pa to rel Th	erature review anuscript number (if known) the interest of transparency ated to the content of your rties whose interests may be transparency and does not a ationship/activity/interest,	lizumab for the treatment  i; we ask you to disclose al manuscript. "Related" me e affected by the content o necessarily indicate a bias it is preferable that you do	of advanced cervical adenocarcinoma: case report and I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript. Disclosure represents a commitment of the solution of the manuscript of the manuscript. Disclosure represents a commitment of the solution of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript of the ma	
to me	the epidemiology of hyperte edication, even if that medic	ension, you should declare ation is not mentioned in pport for the work reporte	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.  Ed in this manuscript without time limit. For all other iten	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	I planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone		
		Time frame: past	t 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	X_None		

Consulting fees

4

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone				
6	Payment for expert testimony	XNone				
7	Support for attending meetings and/or travel	XNone				
8	Patents planned, issued or pending	XNone				
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone				
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone				
11	Stock or stock options	XNone				
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None				
13	Other financial or non- financial interests	XNone				
Ple	Please summarize the above conflict of interest in the following box:					

None.			

Yo Ma lite Ma In rel pa to rel Th	erature review anuscript number (if known) the interest of transparency ated to the content of your rties whose interests may be transparency and does not r ationship/activity/interest,	izumab for the treatment : , we ask you to disclose al manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you de	of advanced cervical adenocarcinoma: case report and all relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment all fyou are in doubt about whether to list a o so.
to me	the epidemiology of hyperte edication, even if that medic	ension, you should declare ation is not mentioned in oport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  End in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

4

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone				
6	Payment for expert testimony	XNone				
7	Support for attending meetings and/or travel	XNone				
8	Patents planned, issued or pending	XNone				
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone				
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone				
11	Stock or stock options	XNone				
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None				
13	Other financial or non- financial interests	XNone				
Please summarize the above conflict of interest in the following box:						

None.			